Onconase, a first-in-class product candidate from Alfacell’s proprietary ribonuclease (RNase) technology has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. Onconase, is currently being evaluated as a treatment for unresectable malignant mesothelioma (UMM) in a confirmatory Phase IIIb clinical trial.
David Strunce, president and CEO of Scientific Protein Laboratories (SPL), said: “We are pleased to have the opportunity to continue the collaboration with the Alfacell team into the commercial stage.”